Cannabinoids pp 327-365 | Cite as

Effects of Cannabinoids on Neurotransmission

  • B. Szabo
  • E. Schlicker
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 168)


The CB1 cannabinoid receptor is widely distributed in the central and peripheral nervous system. Within the neuron, the CB1 receptor is often localised in axon terminals, and its activation leads to inhibition of transmitter release. The consequence is inhibition of neurotransmission via a presynaptic mechanism. Inhibition of glutamatergic, GABAergic, glycinergic, cholinergic, noradrenergic and serotonergic neurotransmission has been observed in many regions of the central nervous system. In the peripheral nervous system, CB1 receptor-mediated inhibition of adrenergic, cholinergic and sensory neuroeffector transmission has been frequently observed. It is characteristic for the ubiquitous operation of CB1 receptor-mediated presynaptic inhibition that antagonistic components of functional systems (for example, the excitatory and inhibitory inputs of the same neuron) are simultaneously inhibited by cannabinoids. Inhibition of voltage-dependent calcium channels, activation of potassium channels and direct interference with the synaptic vesicle release mechanism are all implicated in the cannabinoid-evoked inhibition of transmitter release. Many presynaptic CB1 receptors are subject to an endogenous tone, i.e. they are constitutively active and/or are continuously activated by endocannabinoids. Compared with the abundant data on presynaptic inhibition by cannabinoids, there are only a few examples for cannabinoid action on the somadendritic parts of neurons in situ.


Acetylcholine Axon terminal CB1 cannabinoid receptor GABA Glutamate Neurotransmission Noradrenaline Presynaptic inhibition Transmitter release 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Acquas E, Pisanu A, Marrocu P, Di Chiara G (2000) Cannabinoid CB1 receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur J Pharmacol 401:179–185PubMedCrossRefGoogle Scholar
  2. Acquas E, Pisanu A, Marrocu P, Goldberg SR, Di Chiara G (2001) Δ 9-Tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. Eur J Pharmacol 419:155–161PubMedCrossRefGoogle Scholar
  3. Ahluwalia J, Urban L, Bevan S, Nagy I (2003) Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 17:2611–2618PubMedCrossRefGoogle Scholar
  4. Akinshola BE, Taylor RE, Ogunseitan AB, Onaivi ES (1999) Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP. Naunyn-Schmiedeberg’s Arch Pharmacol 360:242–248CrossRefGoogle Scholar
  5. Al-Hayani A, Davies SN (2000) Cannabinoid receptor mediated inhibition of excitatory synaptic transmission in the rat hippocampal slice is developmentally regulated. Br J Pharmacol 131:663–665PubMedCrossRefGoogle Scholar
  6. Ameri A, Simmet T (2000) Effects of 2-arachidonoylglycerol, an endogenous cannabinoid, on neuronal activity in rat hippocampal slices. Naunyn-Schmiedeberg’s Arch Pharmacol 361:265–272CrossRefGoogle Scholar
  7. Ameri A, Wilhelm A, Simmet T (1999) Effects of the endogenous cannabinoid, anandamide, on neuronal activity in rat hippocampus slices. Br J Pharmacol 126:1831–1839PubMedCrossRefGoogle Scholar
  8. Auclair N, Otani S, Soubrie P, Crepel F (2000) Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 83:3287–3293PubMedGoogle Scholar
  9. Azad SC, Eder M, Marsicano G, Lutz B, Zieglgänsberger W, Rammes G (2003) Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 10:116–128PubMedCrossRefGoogle Scholar
  10. Barann M, Molderings G, Brüss M, Bönisch H, Urban BW, Göthert M (2002) Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137:589–596PubMedCrossRefGoogle Scholar
  11. Begg M, Dale N, Llaudet E, Molleman A, Parsons ME (2002) Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longitudinal muscle preparation of the guinea-pig ileum. Br J Pharmacol 137:1298–1304PubMedCrossRefGoogle Scholar
  12. Brown SP, Brenowitz SD, Regehr WG (2003a) Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nat Neurosci 6:1048–1057PubMedCrossRefGoogle Scholar
  13. Brown TM, Brotchie JM, Fitzjohn SM (2003b) Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. J Neurosci 23:11073–11077PubMedGoogle Scholar
  14. Cadogan A-K, Alexander SPH, Boyd AE, Kendall DA (1997) Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem 69:1131–1137PubMedGoogle Scholar
  15. Carta G, Nava F, Gessa GL (1998) Inhibition of hippocampal acetylcholine release after acute and repeated Δ9-tetrahydrocannabinol in rats. Brain Res 809:1–4PubMedCrossRefGoogle Scholar
  16. Caulfield MP, Brown DA (1992) Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106:231–232PubMedGoogle Scholar
  17. Chan PKY, Yung W-H (1998) Occlusion of the presynaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium. Neurosci Lett 249:57–60PubMedCrossRefGoogle Scholar
  18. Chan PKY, Chan SCY, Yung W-H (1998) Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist. Neuroreport 9:671–675PubMedGoogle Scholar
  19. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P (2001) Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 20:7033–7040PubMedCrossRefGoogle Scholar
  20. Christopoulos A, Coles P, Lay L, Lew MJ, Angus JA (2001) Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Br J Pharmacol 132:1281–1291PubMedCrossRefGoogle Scholar
  21. Compton DR, Harris LS, Lichtman AH Martin BR (1996) Marihuana. Pharmacological aspects of drug dependence. In: Schuster CR, KuharM J (eds) Handbook of Experimental Pharmacology. Springer, Heidelberg, pp 83–158Google Scholar
  22. Coutts AA, Pertwee RG (1997) Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 121:1557–1566PubMedGoogle Scholar
  23. Croci T, Manara L, Aureggi G, Guagnini F, Rinaldi-Carmona M, Maffrand J-P, Le Fur G, Mukenge S, Ferla G (1998) In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 125:1393–1395PubMedCrossRefGoogle Scholar
  24. Daniel H, Crepel F (2001) Control of Ca2+ influx by cannabinoid and metabotropic glutamate receptors in rat cerebellar cortex requires K+ channels. J Physiol (Lond) 537:793–800PubMedCrossRefGoogle Scholar
  25. Deadwyler SA, Hampson RE, Mu J, Whyte A, Childers S (1995) Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther 273:734–743PubMedGoogle Scholar
  26. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HHO, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, Moore L (1997) Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100:1538–1546PubMedCrossRefGoogle Scholar
  27. Diana MA, Marty A (2003) Characterization of depolarization-induced suppression of inhibition using paired interneuron-Purkinje cell recordings. J Neurosci 23:5906–5918PubMedGoogle Scholar
  28. Diana MA, Levenes C, Mackie K, Marty A (2002) Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J Neurosci 22:200–208PubMedGoogle Scholar
  29. Ellington HC, Cotter MA, Cameron NE, Ross RA (2002) The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology 42:966–975PubMedCrossRefGoogle Scholar
  30. Engler B, Szabo B (2003) Cannabinoids inhibit striatopallidal neurotransmission in mice. Naunyn-Schmiedeberg’s Arch Pharmacol 367:R85Google Scholar
  31. Engler B, Szabo B (2004) Characterization of the effects of cannabinoids on synaptic transmission between caudate-putamen and globus pallidus. Naunyn-Schmiedeberg’s Arch Pharmacol 369:R80Google Scholar
  32. Fan P (1995) Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 73:907–910PubMedGoogle Scholar
  33. Ferraro L, Tomasini MC, Gessa GL, Bebe BW, Tanganelli S, Antonelli T (2001) The cannabinoid receptor agonist WIN 55, 212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cerebral Cortex 11:728–733PubMedCrossRefGoogle Scholar
  34. Fränkel S (1903) Chemie und Pharmakologie des Haschisch. Naunyn-Schmiedeberg’s Arch Exp Pathol Pharmakol 49:266–284Google Scholar
  35. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017–1066PubMedGoogle Scholar
  36. Garcia DE, Brown S, Hille B, Mackie K (1998) Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J Neurosci 18:2834–2841PubMedGoogle Scholar
  37. Gerdeman G, Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85:468–471PubMedGoogle Scholar
  38. Gessa GL, Casu MA, Carta G, Mascia MS (1998) Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur J Pharmacol 355:119–124PubMedCrossRefGoogle Scholar
  39. Gifford AN, Ashby Jr CR (1996) Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J Pharmacol Exp Ther 277:1431–1436PubMedGoogle Scholar
  40. Gifford AN, Samiian L, Gatley JS, Ashby Jr CR (1997a) Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. Eur J Pharmacol 324:187–192PubMedCrossRefGoogle Scholar
  41. Gifford AN, Tang Y, Gatley SJ, Volkow ND, Lan R, Makriyannis A (1997b) Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett 238:84–86PubMedCrossRefGoogle Scholar
  42. Gifford AN, Bruneus M, Gatley SJ, Volkow ND (2000) Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes. Br J Pharmacol 131:645–650PubMedCrossRefGoogle Scholar
  43. Glass M, Dragunow M, Faull RLM (2000) The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the humanbasal ganglia inHuntington’s disease. Neuroscience 97:505–519PubMedCrossRefGoogle Scholar
  44. Göbel I, Trendelenburg AU, Cox SL, Meyer A, Starke K (2000) Electrically evoked release of [3H] noradrenaline from mouse cultured sympathetic neurons: release-modulating heteroreceptors. J Neurochem 75:2087–2094PubMedGoogle Scholar
  45. Hájos N, Freund TF (2002) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43:503–510PubMedGoogle Scholar
  46. Hájos N, Katona I, Naiem SS, Mackie K, Ledent C, Mody I, Freund TF (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12:3239–3249PubMedGoogle Scholar
  47. Hájos N, Ledent C, Freund TF (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106:1–4PubMedGoogle Scholar
  48. Hampson RE, Mu J, Deadwyler SA (2000) Cannabinoid and kappa opioid receptors reduce potassium K current via activation of Gs proteins in cultured hippocampal neurons. J Neurophysiol 84:2356–2364PubMedGoogle Scholar
  49. Henry DJ, Chavkin C (1995) Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci Lett 186:91–94PubMedCrossRefGoogle Scholar
  50. Herkenham M, Lynn AB, De Costa BR, Richfield EK (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267–274PubMedCrossRefGoogle Scholar
  51. Himmi T, Perrin J, El Ouazzani T, Orsini J-C (1998) Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. Eur J Pharmacol 359:49–54PubMedCrossRefGoogle Scholar
  52. Hoffman AF, Lupica CR (2000) Mechanisms of cannabinoid inhibition of GABAA synaptic transmission in the hippocampus. J Neurosci 20:2470–2479PubMedGoogle Scholar
  53. Hoffman AF, Lupica CR (2001) Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. J Neurophysiol 85:72–83PubMedGoogle Scholar
  54. Hoffman AF, Oz M, Caulder T, Lupica CR (2003a) Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci 23:4815–4820PubMedGoogle Scholar
  55. Hoffman AF, Riegel AC, Lupica CR (2003b) Functional localization of cannabinoid receptors and endogenous cannabinoid production in distinct neuron populations of the hippocampus. Eur J Neurosci 18:524–534PubMedCrossRefGoogle Scholar
  56. Huang C-C, Lo S-W, Hsu K-S (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol (Lond) 532:731–748PubMedGoogle Scholar
  57. Huang C-C, Chen Y-L, Lo S-W, Hsu K-S (2002) Activation of cAMP-dependent protein kinase suppresses the presynaptic cannabinoid inhibition of glutamatergic transmission at corticostriatal synapses. Mol Pharmacol 61:578–585PubMedGoogle Scholar
  58. Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH, Nie J, Lewis D, Reggio PH (2002) N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28 (192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 62:1274–1287PubMedCrossRefGoogle Scholar
  59. Irving AJ, Coutts AA, Harvey J, Rae MG, Mackie K, Bewick GS, Pertwee RG (2000) Functional expression of cell surface cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neuroscience 98:253–262PubMedCrossRefGoogle Scholar
  60. Ishac EJN, Jiang L, Lake KD, Varga K, Abood ME, Kunos G (1996) Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023–2028PubMedGoogle Scholar
  61. Izzo AA, Mascolo N, Borrelli F, Capasso F (1998) Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br J Pharmacol 124:1363–1368PubMedGoogle Scholar
  62. Jennings EA, Vaughan CW, Christie MJ (2001) Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro. J Physiol 534:805–812PubMedCrossRefGoogle Scholar
  63. Kathmann M, Bauer U, Schlicker E, Göthert M (1999) Cannabinoid CB1 receptor-mediated inhibition of NMDA-and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn-Schmiedeberg’s Arch Pharmacol 359:466–470CrossRefGoogle Scholar
  64. Kathmann M, Weber B, Schlicker E (2001a) Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6 J mice. Naunyn-Schmiedeberg’s Arch Pharmacol 363:50–56CrossRefGoogle Scholar
  65. Kathmann M, Weber B, Zimmer A, Schlicker E (2001b) Enhanced acetylcholine release in the hippocampus of cannabinoid CB1 receptor-deficient mice. Br J Pharmacol 132:1169–1173PubMedCrossRefGoogle Scholar
  66. Katona I, Sperlagh B, Sik A, Köfalvi A, Vizi ES, Mackie K, Freund TF (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544–4558PubMedGoogle Scholar
  67. Katona I, Sperlagh B, Magloczky Z, Santha E, Köfalvi A, Czirjak S, Mackie K, Vizi ES, Freund TF (2000) GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100:797–804PubMedCrossRefGoogle Scholar
  68. Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, Freund TF (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21:9506–9518PubMedGoogle Scholar
  69. Kim DJ, Thayer SA (2000) Activation of CB1 cannabinoid receptors inhibits neurotransmitter release from identified synaptic sites in rat hippocampal cultures. Brain Res 852:398–405PubMedCrossRefGoogle Scholar
  70. Köfalvi A, Vizi ES, Ledent C, Sperlagh B (2003) Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. Eur J Neurosci 18:1973–1978PubMedGoogle Scholar
  71. Kolasiewicz W, Wolfarth S, Ossowska K (1988) The role of the ventromedial thalamic nucleus in the catalepsy evoked from the substantia nigra pars reticulata in rats. Neurosci Lett 90:219–223PubMedCrossRefGoogle Scholar
  72. Kouznetsova M, Kelley B, Shen M, Thayer SA (2002) Desensitization of cannabinoi dmediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. Mol Pharmacol 61:477–485PubMedCrossRefGoogle Scholar
  73. Kreitzer AC, Regehr WG (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717–727PubMedCrossRefGoogle Scholar
  74. Kreitzer AC, Carter AG, Regehr WG (2002) Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum. Neuron 34:787–796PubMedCrossRefGoogle Scholar
  75. Lay L, Angus JA, Wright CE (2000) Pharmacological characterisation of cannabinoid CB1 receptors in the rat and mouse. Eur J Pharmacol 391:151–161PubMedCrossRefGoogle Scholar
  76. Levenes C, Daniel H, Soubrie P, Crepel F (1998) Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol (Lond) 510:867–879PubMedCrossRefGoogle Scholar
  77. Lever IJ, Malcangio M (2002) CB1 receptor antagonist SR141716A increases capsaicinevoked release of Substance P fromthe adult mouse spinal cord. Br J Pharmacol 135:21–24PubMedGoogle Scholar
  78. Lopez-Redondo F, Lees GM, Pertwee RG (1997) Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurones of the guinea-pig ileum. Br J Pharmacol 122:330–334PubMedGoogle Scholar
  79. Mackie K, Hille B (1992) Cannabinoids inhibit N-type calcium channels in neuroblastomaglioma cells. Proc Natl Acad Sci USA 89:3825–3829PubMedGoogle Scholar
  80. Mackie K, Devane WA, Hille B (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N 18 neuroblastoma cells. Mol Pharmacol 44:498–503PubMedGoogle Scholar
  81. Mackie K, Lai Y, Westenbroek R, Mitchell R (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15:6552–6561PubMedGoogle Scholar
  82. Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M (2001) Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31:463–475PubMedCrossRefGoogle Scholar
  83. Mailleux P, Vanderhaeghen J-J (1992) Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48:655–668PubMedCrossRefGoogle Scholar
  84. Maingret F, Patel AJ, Lazdunski M, Honore E (2001) The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1. EMBO J 20:47–54PubMedCrossRefGoogle Scholar
  85. Malinowska B, Godlewski G, Bucher B, Schlicker, E (1997) Cannabinoid CB1 receptormediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn-Schmiedeberg’s Arch Pharmacol 356:197–202CrossRefGoogle Scholar
  86. Malinowska B, Piszcz J, Koneczny B, Hryniewicz A, Schlicker E (2001) Modulation of the cardiac autonomic transmission of pithed rats by presynaptic opioid OP4 and cannabinoid CB1 receptors. Naunyn-Schmiedeberg’s Arch Pharmacol 364:233–241Google Scholar
  87. Malone DT, Taylor DA (1999) Modulation by fluoxetine of striatal dopamine release following Δ9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br J Pharmacol 128:21–26PubMedCrossRefGoogle Scholar
  88. Mang CF, Erbelding D, Kilbinger H (2001) Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 receptors. Br J Pharmacol 134:161–167PubMedCrossRefGoogle Scholar
  89. Manzoni OJ, Bockaert J (2001) Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens. Eur J Pharmacol 412:R3–R5PubMedCrossRefGoogle Scholar
  90. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, Di Marzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–534PubMedCrossRefGoogle Scholar
  91. Matsuda LA, Bonner TI, Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327:535–550PubMedCrossRefGoogle Scholar
  92. McAllister SD, Griffin G, Satin LS, Abood ME (1999) Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system. J Pharmacol Exp Ther 291:618–626PubMedGoogle Scholar
  93. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL (2004) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24:53–62PubMedGoogle Scholar
  94. Mishima K, Egashira N, Matsumoto Y, Iwasaki K, Fujiwara M (2002) Involvement of reduced acetylcholine release in Δ9-tetrahydrocannabinol-induced impairment of spatial memory in the 8-arm radial maze. Life Sci 72:397–407PubMedCrossRefGoogle Scholar
  95. Misner DL, Sullivan JM (1999) Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 19:6795–6805PubMedGoogle Scholar
  96. Molderings GJ, Likungu J, Göthert M (1999) Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn-Schmiedeberg’s Arch Pharmacol 360:157–164Google Scholar
  97. Morisset V, Urban L (2001) Cannabinoid-induced presynaptic inhibition of glutam’ EPSCs in substantia gelatinosa neurons of the rat spinal cord. J Neurophysiol 86:40–48PubMedGoogle Scholar
  98. Mu J, Zhuang S-Y, Hampson RE, Deadwyler SA (2000) Protein kinase-dependent phosphorylation and cannabinoid receptor modulation of potassium A current (IA) in cultured rat hippocampal neurons. Pflügers Arch 439:541–546PubMedCrossRefGoogle Scholar
  99. Nakatsuka T, Chen H-X, Roper SN, Gu JG (2003) Cannabinoid receptor-1 activation suppresses inhibitory synaptic activity in human dentate gyrus. Neuropharmacology 45:116–121PubMedCrossRefGoogle Scholar
  100. Nakazi M, Bauer M, Nickel T, Kathmann M, Schlicker E (2000) Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn-Schmiedeberg’s Arch Pharmacol 361:19–24Google Scholar
  101. Nemeth J, Helyes Z, Than M, Jakab B, Pinter E, Szolcsanyi J (2003) Concentration-dependent dual effect of anandamide on sensory neuropeptide release from isolated rat tracheae. Neurosci Lett 336:89–92PubMedCrossRefGoogle Scholar
  102. Nicholson RA, Liao C, Zheng J, David LS, Coyne L, Errington AC, Singh G, Lees G (2003) Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res 978:194–204PubMedCrossRefGoogle Scholar
  103. Niederhoffer N, Szabo B (1999) Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 126:457–466PubMedGoogle Scholar
  104. Niederhoffer N, Hansen HH, Fernandez-Ruiz JJ, Szabo B (2001) Effects of cannabinoids on adrenaline release from adrenal medullary cells. Br J Pharmacol 134:1319–1327PubMedCrossRefGoogle Scholar
  105. Niederhoffer N, Schmid K, Szabo B (2003) The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn-Schmiedeberg’s Arch Pharmacol 367:434–443CrossRefGoogle Scholar
  106. Nogueron IM, Porgilsson B, Schneider WE, Stucky CL, Hillard CJ (2001) Cannabinoid receptor agonists inhibit depolarization-induced calcium influx in cerebellar granule neurons. J Neurochem 79:371–381PubMedCrossRefGoogle Scholar
  107. Ohno-Shosaku T, Maejima T, Kano M (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29:729–738PubMedGoogle Scholar
  108. Oz M, Ravindran A, Diaz-Ruiz O, Zhang L, Morales M (2003) The endogenous cannabinoid anandamide inhibits α7 nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. J Pharmacol Exp Ther 306:1003–1010PubMedCrossRefGoogle Scholar
  109. Pan X, Ikeda SR, Lewis DL (1996) Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol Pharmacol 49:707–714PubMedGoogle Scholar
  110. Patel S, Hillard CJ (2001) Cannabinoid CB1 receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther 297:629–637PubMedGoogle Scholar
  111. Pertwee RG, Fernando SR (1996) Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol 118:2053–2058PubMedGoogle Scholar
  112. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD (1992) Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and themyenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol 105:980–984PubMedGoogle Scholar
  113. Pertwee RG, Fernando SR, Griffin G, Ryan W, Razdan RK, Compton DR, Martin BR (1996a) Agonist-antagonist characterization of 6’-cyanohex-2’-yne-Δ8-tetrahydrocannabinol in two isolated tissue preparations. Eur J Pharmacol 315:195–201PubMedCrossRefGoogle Scholar
  114. Pertwee RG, Fernando SR, Nash JE, Coutts AA (1996b) Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol 118:2199–2205PubMedGoogle Scholar
  115. Pertwee RG, Ross RA, Craib S, Thomas A (2002) (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456:99–106PubMedCrossRefGoogle Scholar
  116. Ralevic V (2003) Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. Eur J Pharmacol 472:1–21PubMedCrossRefGoogle Scholar
  117. Ralevic V, Kendall DA (2001) Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol 418:117–125PubMedCrossRefGoogle Scholar
  118. Ralevic V, Kendall DA (2002) Cannabinoids inhibit pre-and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. Eur J Pharmacol 444:171–181PubMedCrossRefGoogle Scholar
  119. Richardson JD, Kilo S, Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111–119PubMedCrossRefGoogle Scholar
  120. Riegel AC, Williams JT, Lupica CR (2003) Cannabinoid receptor activation depresses GABAB mediated synaptic responses in dopamine neurons. In: 2003 Symposium on the cannabinoids. International Cannabinoid Research Society, Burlington, p 23Google Scholar
  121. Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ (2001) Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 21:109–116PubMedGoogle Scholar
  122. Rodriguez JJ, Mackie K, Pickel VM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in µ-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 21:823–833PubMedGoogle Scholar
  123. Rubovitch V, Gafni M, Sarne Y (2002) The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Mol Brain Res 101:93–102PubMedCrossRefGoogle Scholar
  124. Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, Casti P, Vargiu R, Pani L (2003) Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 306:363–370PubMedCrossRefGoogle Scholar
  125. Sanudo-Pena MC, Tsou K, Walker JM (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65:703–713PubMedGoogle Scholar
  126. Schlicker E, Kathmann M (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565–572PubMedCrossRefGoogle Scholar
  127. Schlicker E, Timm J, Göthert M (1996) Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn-Schmiedeberg’s Arch Pharmacol 354:791–795Google Scholar
  128. Schlicker E, Timm J, Zentner J, Göthert M (1997) Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn-Schmiedeberg’s Arch Pharmacol 356:583–589Google Scholar
  129. Schlicker E, Liedtke S, Flau K, Kathmann M (2002) Further evidence that the cannabinoid receptor inhibiting noradrenaline release in the guinea-pig brain belongs to the CB1 subtype and is subject to an endogenous tone. Pharmacologist 44(Suppl 1):A112Google Scholar
  130. Schlicker E, Redmer A, Werner A, Kathmann M (2003) Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release. Br J Pharmacol 140:323–328PubMedCrossRefGoogle Scholar
  131. Schultheiß T, Flau K, Redmer A, Kathmann M, Reggio PH, Seltzman HH, Schlicker E (2004) The facilitatory effect of SR141716 on transmitter release in guinea-pig hippocampus is due to its inverse agonist activity at cannabinoid CB1 receptors. Naunyn-Schmiedeberg’s Arch Pharmacol 369(Suppl 1):R84Google Scholar
  132. Schweitzer P (2000) Cannabinoids decrease the K+ M-current in hippocampal CA1 neurons. J Neurosci 20:51–58PubMedGoogle Scholar
  133. Seifert R, Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg’s Arch Pharmacol 366:381–416CrossRefGoogle Scholar
  134. Shen M, Thayer SA (1999) Δ9-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55:8–13PubMedGoogle Scholar
  135. Shen M, Piser TM, Seybold VS, Thayer SA (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322–4334PubMedGoogle Scholar
  136. Starke K, Göthert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864–989PubMedGoogle Scholar
  137. Steffens M, Szabo B, Klar M, Rominger A, Zentner J, Feuerstein TJ (2003) Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience 120:456–465CrossRefGoogle Scholar
  138. Storr M, Sibaev A, Marsicano G, Lutz B, Schusdziarra V, Timmermans JP, Allescher HD (2004) Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am J Physiol Gastrointest Liver Physiol 286:G110–G117PubMedGoogle Scholar
  139. Straiker A, Sullivan JM (2003) Cannabinoid receptor activation differentially modulates ion channels in photoreceptors of the tiger salamander. J Neurophysiol 89:2647–2654PubMedGoogle Scholar
  140. Straiker AJ, Borden CR, Sullivan JM (2002) G-protein alpha subunit isoforms couple differentially to receptors that mediate presynaptic inhibition at rat hippocampal synapses. J Neurosci 22:2460–2468PubMedGoogle Scholar
  141. Sullivan JM (1999) Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons. J Neurophysiol 82:1286–1294PubMedGoogle Scholar
  142. Szabo B, Dörner L, Pfreundtner C, Nörenberg W, Starke K (1998) Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85:395–403PubMedCrossRefGoogle Scholar
  143. Szabo B, Müller T, Koch H (1999) Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 73:1084–1089PubMedCrossRefGoogle Scholar
  144. Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C (2000) Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 97:89–97PubMedCrossRefGoogle Scholar
  145. Szabo B, Nordheim U, Niederhoffer N (2001) Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 297:819–826PubMedGoogle Scholar
  146. Szabo B, Siemes S, Wallmichrath I (2002) Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci 15:2057–2061PubMedCrossRefGoogle Scholar
  147. Szabo B, Than M, Wallmichrath I, Thorn D (2004) Analysis of the effects of cannabinoids on synaptic transmission between basket and Purkinje cells in the cerebellar cortex of the rat. J Pharmacol Exp Ther 310:915–925PubMedCrossRefGoogle Scholar
  148. Takahashi KA, Linden DJ (2000) Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. J Neurophysiol 83:1167–1180PubMedGoogle Scholar
  149. Thompson SM, Capogna M, Scanziani M (1993) Presynaptic inhibition in the hippocampus. Trends Neurosci 16:222–227PubMedGoogle Scholar
  150. Timm J, Marr I, Werthwein S, Elz S, Schunack W, Schlicker E (1998) H2 receptor-mediated facilitation and H3 receptor-mediated inhibition of noradrenaline release in the guinea-pig brain. Naunyn-Schmiedeberg’s Arch Pharmacol 357:232–239CrossRefGoogle Scholar
  151. Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M, Matera M, Geppetti P, Bianchi A (2001) Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 21:1104–1109PubMedGoogle Scholar
  152. Trendelenburg AU, Cox SL, Schelb V, Klebroff W, Khairallah, Starke K (2000) Modulation of 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β-adrenoceptors in mouse tissues. Br J Pharmacol 130:321–330PubMedCrossRefGoogle Scholar
  153. Trettel J, Levine ES (2002) Cannabinoids depress inhibitory synaptic inputs received by layer 2/3 pyramidal neurons of the neocortex. J Neurophysiol 88:534–539PubMedGoogle Scholar
  154. Trettel J, Levine ES (2003) Endocannabinoids mediate rapid retrograde signaling at interneuronμ pyramidal neuron synapses of the neocortex. J Neurophysiol 89:2334–2338PubMedGoogle Scholar
  155. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393–411PubMedGoogle Scholar
  156. Turkanis SA, Partlow LM, Karler R (1991) Delta-9-tetrahydrocannabinol depresses inward sodium current in mouse neuroblastoma cells. Neuropharmacology 30:73–77PubMedCrossRefGoogle Scholar
  157. Twitchell W, Brown S, Mackie K (1997) Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 78:43–50PubMedGoogle Scholar
  158. Tzavara ET, Perry KW, Rodriguez DE, Bymaster F, Nomikos GG (2001) The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 426:R3–R4PubMedCrossRefGoogle Scholar
  159. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Witkin JM, Bymaster F, Nomikos GG (2003a) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544–553PubMedCrossRefGoogle Scholar
  160. Tzavara ET, Wade M, Nomikos GG (2003b) Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci 23:9374–9384PubMedGoogle Scholar
  161. Van Vliet BJ, Nievelstein HNMW, Long SK, Kruse CG (2000) CB1 receptor-mediated effects on brain neurotransmitter systems. Eur Neuropsychopharmacol 10(Suppl 3):S182–S183Google Scholar
  162. Vaughan CW, McGregor IS, Christie McDJ (1999) Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 127:935–940PubMedCrossRefGoogle Scholar
  163. Vaughan CW, Connor M, Bagley EE, Christie MJ (2000) Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 57:288–295PubMedGoogle Scholar
  164. Verrico CD, Jentsch JD, Dazzi L, Roth RH (2003) Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat. Synapse 48:178–183PubMedCrossRefGoogle Scholar
  165. Vizi ES, Katona I, Freund TF (2001) Evidence for presynaptic cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the guinea pig lung. Eur J Pharmacol 431:237–244PubMedCrossRefGoogle Scholar
  166. Wallmichrath I, Szabo B (2002a) Analysis of the effect of cannabinoids on GABAergic neurotransmission in the substantia nigra pars reticulata. Naunyn-Schmiedeberg’s Arch Pharmacol 365:326–334CrossRefGoogle Scholar
  167. Wallmichrath I, Szabo B (2002b) Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 113:671–682PubMedCrossRefGoogle Scholar
  168. Wallmichrath I, Szabo B (2003) Effects of cannabinoids on the glutamatergic neurotransmission between nucleus subthalamicus and globus pallidus. Naunyn-Schmiedeberg’s Arch Pharmacol 367:R83Google Scholar
  169. Wang S-J (2003) Cannabinoid CB1 receptor-mediated inhibition of glutamate release from rat hippocampal synaptosomes. Eur J Pharmacol 469:47–55PubMedCrossRefGoogle Scholar
  170. Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588–592PubMedCrossRefGoogle Scholar
  171. Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296:678–682PubMedCrossRefGoogle Scholar
  172. Wu L-G, Saggau P (1997) Presynaptic inhibition of elicited neurotransmitter release. Trends Neurosci 20:204–212PubMedCrossRefGoogle Scholar
  173. Yoshida T, Hashimoto K, Zimmer A, Maejima T, Araishi K, Kano M (2002) The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells. J Neurosci 22:1690–1697PubMedGoogle Scholar
  174. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780–5785PubMedCrossRefGoogle Scholar
  175. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Högestätt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452–457PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • B. Szabo
    • 1
  • E. Schlicker
    • 2
  1. 1.Institut für Experimentelle und Klinische Pharmakologie und ToxikologieAlbert-Ludwigs-UniversitätFreiburgGermany
  2. 2.Institut für Pharmakologie und ToxikologieRheinische Friedrich-Wilhelms-UniversitätBonnGermany

Personalised recommendations